Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography

Therapeutic Drug Monitoring

Volumn 21, Issue 4, 1999, Pages 404-410

  Poirier, Jean Marie ^a   Robidou, Pascal ^a   Jaillon, Patrice ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Indinavir; Liquid chromatography; Solid phase extraction

Indexed keywords

DRUG METABOLITE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE;

ACCURACY; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIGNAL NOISE RATIO; SOLID PHASE EXTRACTION; ULTRAVIOLET SPECTROSCOPY;

ANTI-HIV AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LINEAR MODELS; SENSITIVITY AND SPECIFICITY;

EID: 0032770963     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199908000-00004     Document Type: Article

References (14)

1. Vacca JP, Dorsey BD, Schleif WA, et al. L-735.524, an orally bioavailable HIV-1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. Chiba M, Hensleigh M, Nishime JA et al. Role of CYP3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab Dispos 1996;24:307-14.
5. Balani SK, Woolf EJ, Hoagland VC, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996;24:1389-94.
6. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimocrob Agents Chemother 1998;42:332-8.
7. Stein DS, Fish DG, Bilello JA, et al. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
8. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995,692:45-52.
9. Woolf EJ, Matuszewski BK. Simultaneous determination of unla-beled and deuterium-labeled indinavir in human plasma by highperformance liquid chromatography with tandem mass spectrometric detection. J Pharm Sci 1997;86:193-8.
10. Jayewardene AL, Zhu F, Aweeka FT, Gambertoglio JG. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B 1998;707:203-11.
11. Burger DM, de Graaff M, Wuis EW, et al. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 1997;703:235-41.
12. Flexner C. Pharmacokinetics and pharmacodynamics of HIV protease inhibitors. Infect Med 1996;13:16-23.
13. Cheng YF, Phillips DJ, Neue U. Simple and rugged SPE method for the determination of tetracycline antibiotics in serum by HPLC using a volatile mobile phase. Chromatographia 1997;44:187-90.
14. Poirier JM, Radembino N, Jaillon P. Determination of acyclovir in plasma by solid-phase extraction and column liquid chromatography. Ther Drug Monit 1999;21:129-33.